Product NDC: | 0093-4338 |
Proprietary Name: | Terazosin hydrochloride |
Non Proprietary Name: | Terazosin hydrochloride |
Active Ingredient(s): | 5 mg/1 & nbsp; Terazosin hydrochloride |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0093-4338 |
Labeler Name: | Teva Pharmaceuticals USA Inc |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA075614 |
Marketing Category: | ANDA |
Start Marketing Date: | 20090908 |
Package NDC: | 0093-4338-10 |
Package Description: | 1000 CAPSULE in 1 BOTTLE (0093-4338-10) |
NDC Code | 0093-4338-10 |
Proprietary Name | Terazosin hydrochloride |
Package Description | 1000 CAPSULE in 1 BOTTLE (0093-4338-10) |
Product NDC | 0093-4338 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Terazosin hydrochloride |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20090908 |
Marketing Category Name | ANDA |
Labeler Name | Teva Pharmaceuticals USA Inc |
Substance Name | TERAZOSIN HYDROCHLORIDE |
Strength Number | 5 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] |